Compare Endeavour Silver Corp (EXK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Neurocrine Biosciences Inc — how do they compare? Endeavour Silver Corp trades at $7.55 (market cap $2.36B), while Neurocrine Biosciences Inc trades at $171.85 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.3× Endeavour Silver Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | NBIX | |
|---|---|---|
Market Cap | $2.36B | $17.30B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $180.55 |
52-Week Low | $4.96 | $123.10 |
Enterprise Value | $2.36B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $7.625, down 5.63% today, with a bearish technical signal from moving averages. The company reported a Q1 2026 earnings beat of $0.21 per share versus $0.10 expected, driven by record production. However, 2025 financials show a net loss of $119.1 million despite revenue growth, with negative profit margins and ROE. Analyst consensus is strongly bullish with 11 buy ratings.
Outlook hinges on operational execution and silver price trends. Investment opportunity exists from production growth and potential margin improvement, but risks include sustained negative profitability, high debt-to-asset ratio, and commodity price volatility. Cash flow trends show improvement into 2026, supporting near-term stability.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
